Undisclosed Uro-oncology Program(s)
Uro-oncology (e.g., bladder, kidney, prostate cancers)
Phase 2Active
Key Facts
Indication
Uro-oncology (e.g., bladder, kidney, prostate cancers)
Phase
Phase 2
Status
Active
Company
About Tavanta Therapeutics
Tavanta Therapeutics is a private, clinical-stage biopharmaceutical company founded in 2019 and headquartered in Cambridge, Massachusetts, with a corporate office in King of Prussia, PA. The company is developing a pipeline of specialty small molecule drugs, primarily targeting colorectal cancer and uro-oncology, with a strategy centered on advancing late-stage assets. Led by an experienced management team with deep expertise in drug development and commercialization, Tavanta is positioned as a pre-revenue entity aiming to bring clinically meaningful therapies to market where treatment options are limited.
View full company profile